Drug Trial Radar · NCT05060432
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
153
Actual
Start
Sep 6, 2021
Primary completion
Jul 2024
Study completion Jul 2025
Sponsor
- Lead sponsor
- iTeos Belgium SAIndustry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline; iTeos Therapeutics
- First posted
- Sep 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.
Conditions
- Advanced Cancer
- Lung Cancer
- Head and Neck Cancer
- Melanoma
Interventions
EOS-448Drug
Anti-TIGIT monoclonal antibody
pembrolizumabDrug
Anti-PD-1 monoclonal antibody
inupadenantDrug
A2A receptor antagonist
DostarlimabDrug
Anti-PD-1 monoclonal antibody
SOC chemotherapiesDrug
SOC chemotherapies in 1L mNSCLC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with DLT and Adverse EventsTime frame: From first study treatment administration through Day 21-28 for DLT / Up to 120 days after the last dose
- Recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced solid tumorsTime frame: Up to 48 weeks
- Percentage of participants with Objective Response as determined by InvestigatorTime frame: Until disease progression - Approximately 48 months
Locations
42 sites in 6 countries. Site status is shown where the registry gives one.
University of California San Diego
San Diego, California
Hackensack University Medical Center
Bergen, New Jersey
Cliniques universitaires St Luc-UCL
Brussels, Belgium
Jessa Ziekenhuis
Hasselt, Belgium
UZ Leuven
Leuven, Belgium
CHU Helora
Mons, Belgium
GZA Ziekenhuizen campus Sint-Augustinus
Antwerp, Antwerp, Belgium
Hôpital Saint André
Bordeaux, France
CHU Caen
Caen, France
Centre Georges Francois Leclerc
Dijon, France
Clinique Victor Hugo
Le Mans, France
Centre Oscar Lambret
Lille, France
Centre Léon Bérard
Lyon, France
Institut de Cancerologie Lorraine (ICL)
Nancy, France
Institut de Cancérologie de l'Ouest
Nantes, France
Centre Antoine Lacassagne
Nice, France
Pitié Salpêtrière
Paris, France
CHU de POITIERS
Poitiers, France
ICANS
Strasbourg, France
Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
AUSL Della Romagna - Ospedale S. Maria delle Croci
Ravenna, Italy
IDB Center-Istituto Clinico Humanitas (IRCCS)
Rozzano, Milan, Italy
FPO-IRCCS Candiolo Cancer Insitute
Candiolo, Turin, Italy
Hospital Universitario de Badajoz
Badajoz, Spain
Vall d'Hebron
Barcelona, Spain
Hospital Universitario de Jaen
Jaén, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz - START Madrid
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Quirón Málaga
Málaga, Spain
Hospital Universitario de Navarra
Pamplona, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Fundacion Instituto Valenciano de Oncologia (IVO)
Valencia, Spain
Consorci Hospital Gral Univ Valencia
Valencia, Spain
Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
Valencia, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Hospital Althaia Xarxa Assitencial de Manresa
Manresa, Catalonia, Spain
Addenbrooke's Hospital
Cambridge, United Kingdom
Royal Marsden Hospital (London location)
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.